Strongly Positive Histological Data

Akero Announces Strongly Positive Histological Data Across All Efruxifermin Dose Groups in 16-Week Phase 2a BALANCED Study in NASH Patients

48% fibrosis improvement of at least one stage without worsening of NAS across all dose groups, with a 62% response rate for the 50mg dose group

28% fibrosis improvement of at least two stages across all dose groups, with a 38% response rate for the 50mg dose group

48% NASH resolution without worsening of fibrosis across all dose groups, with a 54% response rate for the 50mg dose group

ir.akerotx.com/news-releases/news-release-details/akero-announces-strongly-positive-histological-data-across-all